U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for global congestive heart failure drugs market
Robust pipeline of drugs under development for congestive heart failure is propelling the growth of the congestive heart failure drugs market. Moreover, the growing approval of new drugs from the Food and Drug Administration (FDA) is again expected to augment the growth of the congestive heart failure drugs market. For instance, in February 2021, Novartis announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. On other hand, lack of awareness and diagnosis rate for the disease such as hypertension which is a major cause of heart failure is acting as a restraint in the global congestive heart failure drugs market . According to a study published in NCBI in 2013, only 49% of patients suffering from hypertension were aware of the diagnosis in high-income countries, and t...